Document 8oLJ27rDgrRGr2K7enEmXwZm
To: 'a.r.schnatter@exxonmobil.com' <a.r.schnatter@exxonmobil.com>;
r.jeffrey.lewis@exxonmobil.com <r.jeffrey.lewis@exxonmobil.com>
From:
Cagen, Stuart Z SCC-DCS/261
</O=SHE LUOU=MSXSCC/CN=RE CI PI ENTS/CN=SC724012>
Cc:
Bcc:
Received Date:
2005-12-1621 :37: 12 GMT
Subject:
RE: BD peer reviewers
I would go beyond the quest for leukemia experts. How about dose response experts or those who can appreciate an epidemiology study with a good exposure assessment.
Roy Shore might have a previous BD connection, but eligibility rules (and how long they apply) are not yet firm.
Other possibilities:
Dr. Jerry M. Rice, (Chair), IARC (Retired) Not eligible: Prior BD via IARC Dr. Nancy Mueller (Vice Chair), Harvard University, School of Public Health Dr. Harvey Checkoway, Washington University Prior BD research experience Dr. Helmut Greim, Technical U. of Munich Dr. Howard Rockette, University of Pittsburgh Dr. John Cherrie, Aberdeen University, Institute of Occupational Medicine Possible not eligible as he was a reviewer of a BD air standard in the UK (Link to the UK Air quality Standard document on BD http://www.defra.gov.uk/environment/airquality/aqS/13butad_2nd/pdf/epaqs_13butad-2nd_full.pdf )
Dr. Robert F. Herrick, Harvard University, School of Public Health Dr. Richard Larson, University of Chicago Medical School Dr. Mark Minden, University of Toronto Dr. Li Guilan, Academy of Preventive Medicine, China Dr. Richard Albertini, University of Vermont, College of Medicin Not eligible: BD researcher and Risk assessment co-author
Stuart Cagen
Shell Chemical LP One Shell Plaza, 91 0 Louisiana, Houston, TX 77002-4916
Tel: +1 713241 1407 Fax: 3325 Other Tel: +1 8326463987 Email: stuart.cagen@shell.com Internet: http://www.shell.com/chemicals
"Business Success through HSSE Excellence"
-----Original Message----From: a.r.schnatter@exxonmobil.com [ mailto:a.r.schnatter@exxonmobil.com] Sent: Friday, December 16, 2005 3:08 PM To: r.jeffrey.lewis@exxonmobil.com Cc: Elizabeth_Moran@americanchemistry.com; Cagen, Stuart Z SCC-DCS/261 Subject: Re: BD peer reviewers
I'm not sure whether leukemogenesis experts are really needed. Most of them will support Irons' view that chemicals causing both types of
SH ELL-MCCLU RG-OS4967
leukemias are pretty rare, if they exist at all. If I'm over-ruled, Richard Larson (from the Shanghai SAB) is excellent, so is John Bennett. I would also strongly recommend Roy Shore, a statisticican more familiar with BO and Sielken-type risk modelling.
A. Robert Schnatter ExxonMobil Biomedical Sciences, Inc. Room LF-246 545 Route 22 East Annadale, NJ 08801-0971 908-730-11 01 908-730-1192(fax)
R Jeffrey
LewiS/East-USI
ExxonMobil
To
A R Schnatter/East-US/ExxonMobil@xom
cc
12/16/05 02: 10
PM Subject
BO peer reviewers
Rob, At the end of the BO workgroup call today, Stuart asked if any the folks on the Shanghi study advisory board might be good candidates for the BO peer review. Stuart mentioned someone named Howard Rocket, but thought there would be others too. Experts in leukemogensis and statistics are what is really needed most. Jeff
R. Jeffrey Lewis ExxonMobil Biomedical Sciences, Inc. Epidemiology & Health Surveillance Section 1545 Route 22 East, P.O. Box 971 Room LF 264 Annandale, NJ 08801-0971 (908)730-1107 (voice) (908)730-1192 (fax) (732)437-0670 (pager) r.jeffrey.lewis@exxonmobil.com
This document and all information contained within this electronic message
SH ELL-MCCLU RG-OS4968
may be privileged, confidential, and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited.
SH ELL-MCCLU RG-OS4969